RET and non-small cell lung carcinoma: Contrary to these findings, a real-world study by Guisier reported a more favorable outcome with ICI monotherapy in RET-rearranged NSCLC, showing an ORR of 37.5% and a median PFS of 7.6 months [76], suggesting a potential variability in response within this population.